Logo image of PCRX

PACIRA BIOSCIENCES INC (PCRX) Stock Fundamental Analysis

NASDAQ:PCRX - Nasdaq - US6951271005 - Common Stock

22.84  +0.48 (+2.15%)

After market: 22.84 0 (0%)

Fundamental Rating

6

Taking everything into account, PCRX scores 6 out of 10 in our fundamental rating. PCRX was compared to 195 industry peers in the Pharmaceuticals industry. PCRX scores excellent on profitability, but there are some minor concerns on its financial health. PCRX is valued quite cheap, while showing a decent growth score. This is a good combination! This makes PCRX very considerable for value investing!


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

PCRX had positive earnings in the past year.
PCRX had a positive operating cash flow in the past year.
Of the past 5 years PCRX 4 years were profitable.
PCRX had a positive operating cash flow in each of the past 5 years.
PCRX Yearly Net Income VS EBIT VS OCF VS FCFPCRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M 150M

1.2 Ratios

PCRX has a better Return On Assets (-5.37%) than 78.49% of its industry peers.
Looking at the Return On Equity, with a value of -10.91%, PCRX is in the better half of the industry, outperforming 76.88% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 6.55%, PCRX belongs to the top of the industry, outperforming 84.95% of the companies in the same industry.
PCRX had an Average Return On Invested Capital over the past 3 years of 4.32%. This is significantly below the industry average of 43.99%.
The last Return On Invested Capital (6.55%) for PCRX is above the 3 year average (4.32%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA -5.37%
ROE -10.91%
ROIC 6.55%
ROA(3y)1.88%
ROA(5y)3.15%
ROE(3y)4.21%
ROE(5y)6.6%
ROIC(3y)4.32%
ROIC(5y)4.07%
PCRX Yearly ROA, ROE, ROICPCRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10 -10 20

1.3 Margins

PCRX's Profit Margin has declined in the last couple of years.
With an excellent Operating Margin value of 13.59%, PCRX belongs to the best of the industry, outperforming 84.41% of the companies in the same industry.
In the last couple of years the Operating Margin of PCRX has grown nicely.
With an excellent Gross Margin value of 73.82%, PCRX belongs to the best of the industry, outperforming 80.11% of the companies in the same industry.
In the last couple of years the Gross Margin of PCRX has remained more or less at the same level.
Industry RankSector Rank
OM 13.59%
PM (TTM) N/A
GM 73.82%
OM growth 3Y-2.79%
OM growth 5Y20.05%
PM growth 3Y-43.17%
PM growth 5YN/A
GM growth 3Y-0.03%
GM growth 5Y-0.43%
PCRX Yearly Profit, Operating, Gross MarginsPCRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 40 60

5

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PCRX is destroying value.
PCRX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for PCRX has been increased compared to 5 years ago.
Compared to 1 year ago, PCRX has an improved debt to assets ratio.
PCRX Yearly Shares OutstandingPCRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
PCRX Yearly Total Debt VS Total AssetsPCRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B 2B

2.2 Solvency

PCRX has an Altman-Z score of 1.74. This is a bad value and indicates that PCRX is not financially healthy and even has some risk of bankruptcy.
PCRX has a better Altman-Z score (1.74) than 65.05% of its industry peers.
PCRX has a debt to FCF ratio of 3.04. This is a good value and a sign of high solvency as PCRX would need 3.04 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 3.04, PCRX belongs to the best of the industry, outperforming 91.40% of the companies in the same industry.
PCRX has a Debt/Equity ratio of 0.51. This is a neutral value indicating PCRX is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.51, PCRX is doing worse than 65.05% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.51
Debt/FCF 3.04
Altman-Z 1.74
ROIC/WACC0.69
WACC9.44%
PCRX Yearly LT Debt VS Equity VS FCFPCRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 2.25 indicates that PCRX has no problem at all paying its short term obligations.
PCRX has a Current ratio of 2.25. This is comparable to the rest of the industry: PCRX outperforms 42.47% of its industry peers.
PCRX has a Quick Ratio of 1.89. This is a normal value and indicates that PCRX is financially healthy and should not expect problems in meeting its short term obligations.
PCRX has a Quick ratio (1.89) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 2.25
Quick Ratio 1.89
PCRX Yearly Current Assets VS Current LiabilitesPCRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 12.72% over the past year.
Measured over the past years, PCRX shows a very strong growth in Earnings Per Share. The EPS has been growing by 22.93% on average per year.
Looking at the last year, PCRX shows a very strong growth in Revenue. The Revenue has grown by 29.50%.
PCRX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.88% yearly.
EPS 1Y (TTM)12.72%
EPS 3Y9.9%
EPS 5Y22.93%
EPS Q2Q%9.72%
Revenue 1Y (TTM)29.5%
Revenue growth 3Y16.25%
Revenue growth 5Y14.88%
Sales Q2Q%2.83%

3.2 Future

Based on estimates for the next years, PCRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.83% on average per year.
The Revenue is expected to grow by 0.74% on average over the next years.
EPS Next Y8.09%
EPS Next 2Y4.99%
EPS Next 3Y9.47%
EPS Next 5Y8.83%
Revenue Next Year2.55%
Revenue Next 2Y2.35%
Revenue Next 3Y5.37%
Revenue Next 5Y0.74%

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
PCRX Yearly Revenue VS EstimatesPCRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M
PCRX Yearly EPS VS EstimatesPCRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4

9

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 7.16, the valuation of PCRX can be described as very cheap.
Based on the Price/Earnings ratio, PCRX is valued cheaply inside the industry as 96.24% of the companies are valued more expensively.
PCRX's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 28.29.
The Price/Forward Earnings ratio is 7.10, which indicates a rather cheap valuation of PCRX.
Based on the Price/Forward Earnings ratio, PCRX is valued cheaply inside the industry as 93.55% of the companies are valued more expensively.
PCRX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 24.44.
Industry RankSector Rank
PE 7.16
Fwd PE 7.1
PCRX Price Earnings VS Forward Price EarningsPCRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, PCRX is valued cheaply inside the industry as 96.24% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of PCRX indicates a rather cheap valuation: PCRX is cheaper than 97.85% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 5.45
EV/EBITDA 5.08
PCRX Per share dataPCRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

PCRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PCRX has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)0.89
PEG (5Y)0.31
EPS Next 2Y4.99%
EPS Next 3Y9.47%

0

5. Dividend

5.1 Amount

No dividends for PCRX!.
Industry RankSector Rank
Dividend Yield N/A

PACIRA BIOSCIENCES INC

NASDAQ:PCRX (1/21/2025, 8:19:45 PM)

After market: 22.84 0 (0%)

22.84

+0.48 (+2.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)N/A N/A
Inst Owners116.83%
Inst Owner Change-0.49%
Ins Owners1.05%
Ins Owner Change7%
Market Cap1.05B
Analysts72
Price Target18.49 (-19.05%)
Short Float %9.67%
Short Ratio5.88
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.37%
Min EPS beat(2)9.93%
Max EPS beat(2)24.81%
EPS beat(4)2
Avg EPS beat(4)7.73%
Min EPS beat(4)-2.59%
Max EPS beat(4)24.81%
EPS beat(8)3
Avg EPS beat(8)0.07%
EPS beat(12)4
Avg EPS beat(12)-6.49%
EPS beat(16)7
Avg EPS beat(16)-5.12%
Revenue beat(2)1
Avg Revenue beat(2)-0.71%
Min Revenue beat(2)-2.6%
Max Revenue beat(2)1.18%
Revenue beat(4)1
Avg Revenue beat(4)-1.05%
Min Revenue beat(4)-2.6%
Max Revenue beat(4)1.18%
Revenue beat(8)1
Avg Revenue beat(8)-2.41%
Revenue beat(12)1
Avg Revenue beat(12)-2.3%
Revenue beat(16)2
Avg Revenue beat(16)-2.21%
PT rev (1m)-5.32%
PT rev (3m)-7.39%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.95%
EPS NY rev (1m)0%
EPS NY rev (3m)1.81%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.64%
Revenue NY rev (1m)-0.1%
Revenue NY rev (3m)0.06%
Valuation
Industry RankSector Rank
PE 7.16
Fwd PE 7.1
P/S 1.22
P/FCF 5.45
P/OCF 5.17
P/B 1.41
P/tB 3.41
EV/EBITDA 5.08
EPS(TTM)3.19
EY13.97%
EPS(NY)3.22
Fwd EY14.09%
FCF(TTM)4.19
FCFY18.35%
OCF(TTM)4.41
OCFY19.33%
SpS18.67
BVpS16.24
TBVpS6.7
PEG (NY)0.89
PEG (5Y)0.31
Profitability
Industry RankSector Rank
ROA -5.37%
ROE -10.91%
ROCE 9.64%
ROIC 6.55%
ROICexc 10.46%
ROICexgc 24.8%
OM 13.59%
PM (TTM) N/A
GM 73.82%
FCFM 22.45%
ROA(3y)1.88%
ROA(5y)3.15%
ROE(3y)4.21%
ROE(5y)6.6%
ROIC(3y)4.32%
ROIC(5y)4.07%
ROICexc(3y)6.29%
ROICexc(5y)6.55%
ROICexgc(3y)29.94%
ROICexgc(5y)22.81%
ROCE(3y)6.36%
ROCE(5y)5.99%
ROICexcg growth 3Y-7.41%
ROICexcg growth 5Y10.67%
ROICexc growth 3Y-15.58%
ROICexc growth 5Y0.45%
OM growth 3Y-2.79%
OM growth 5Y20.05%
PM growth 3Y-43.17%
PM growth 5YN/A
GM growth 3Y-0.03%
GM growth 5Y-0.43%
F-Score6
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 0.51
Debt/FCF 3.04
Debt/EBITDA 2
Cap/Depr 13.52%
Cap/Sales 1.19%
Interest Coverage 9.06
Cash Conversion 105.52%
Profit Quality N/A
Current Ratio 2.25
Quick Ratio 1.89
Altman-Z 1.74
F-Score6
WACC9.44%
ROIC/WACC0.69
Cap/Depr(3y)71.34%
Cap/Depr(5y)91.2%
Cap/Sales(3y)5.08%
Cap/Sales(5y)5.29%
Profit Quality(3y)415.67%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.72%
EPS 3Y9.9%
EPS 5Y22.93%
EPS Q2Q%9.72%
EPS Next Y8.09%
EPS Next 2Y4.99%
EPS Next 3Y9.47%
EPS Next 5Y8.83%
Revenue 1Y (TTM)29.5%
Revenue growth 3Y16.25%
Revenue growth 5Y14.88%
Sales Q2Q%2.83%
Revenue Next Year2.55%
Revenue Next 2Y2.35%
Revenue Next 3Y5.37%
Revenue Next 5Y0.74%
EBIT growth 1Y73.26%
EBIT growth 3Y13.01%
EBIT growth 5Y37.92%
EBIT Next Year21.67%
EBIT Next 3Y17.82%
EBIT Next 5Y12.49%
FCF growth 1Y108.99%
FCF growth 3Y52.67%
FCF growth 5Y32.31%
OCF growth 1Y61.24%
OCF growth 3Y26.17%
OCF growth 5Y25.89%